Background: Inflammation is a key element behind the pathophysiology of cerebral aneurysm formation and rupture. Aspirin is a potent inhibitor of cyclooxygenase-2 (COX), which plays a critical role in the expression of immune modulators known to contribute to cerebral aneurysm formation and rupture. Currently, there are no pharmacological therapies for patients with cerebral aneurysms. Both endovascular and microsurgical interventions may be associated with significant morbidity and mortality. Potentially, a medical alternative that prevents aneurysm progression and rupture may be a beneficial therapy for a significant number of patients. Summary: In animal models, treatment with aspirin and genetic inactivation of COX-2 decreases aneurysm formation and rupture. Selective inhibition of COX-1 did not decrease aneurysm rupture, suggesting that selection inhibition of COX-2 may be critical in thwarting aneurysm progression. Walls of ruptured human intracranial aneurysms have higher levels of COX-2 and microsomal prostaglandin E2 synthase 1 (mPGES-1), both of which are known to be inhibited by aspirin. In a pilot study, patients undergoing microsurgical clipping had attenuated expression of COX-2, mPGES-1, and macrophages in aneurysm walls after 3 months of aspirin therapy versus those that did not receive aspirin. Additionally, in patients undergoing endovascular therapy, local circulating expression of chemokines and COX-2 were increased in blood samples taken from within aneurysm domes as compared to peripheral blood sample controls. Treatment with aspirin also resulted in decreased expression of COX-2 within leukocytes within aneurysms as compared to peripheral blood samples. Novel molecular imaging with ferumoxytol-enhanced MRI may help in the identification of patients at increased risk for aneurysm rupture and assessment of a response to aspirin therapy. Key Messages: Aspirin has been found to be a safe in patients harboring cerebral aneurysms and clinical studies provide evidence that it may decrease the overall rate of rupture. Furthermore, aspirin is an accessible and inexpensive medicine for patients who may not have access to endovascular or microsurgical treatment or for patients who are deemed low risk of aneurysm rupture, high risk for intervention, or both. Future clinical trials are indicated to determine the overall effect of aspirin on aneurysm progression and rupture. This review provides an update on the potential mechanisms and benefits of aspirin in the treatment of cerebral aneurysms.

Keywords:
Aneurysm, Cerebral, Inflammation, Rupture, Subarachnoid hemorrhage, Aspirin, Antithrombotic, Cyclooxygenase
1.
Suarez JI, Tarr RW, Selman WR: Aneurysmal subarachnoid hemorrhage. N Engl J Med 2006;354:387-396.
2.
van Gijn J, Rinkel GJ: Subarachnoid haemorrhage: diagnosis, causes and management. Brain 2001;124:249-278.
3.
Rincon F, Rossenwasser RH, Dumont A: The epidemiology of admissions of nontraumatic subarachnoid hemorrhage in the United States. Neurosurgery 2013;73:217-222; discussion 222-223.
4.
Hop JW, Rinkel GJ, Algra A, van Gijn J: Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 1997;28:660-664.
5.
Mayer SA, Kreiter KT, Copeland D, et al: Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology 2002;59:1750-1758.
6.
Brilstra EH, Rinkel GJ, van der Graaf Y, et al: Quality of life after treatment of unruptured intracranial aneurysms by neurosurgical clipping or by embolisation with coils. A prospective, observational study. Cerebrovasc Dis 2004;17:44-52.
7.
Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G: European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis 2013;35:93-112.
8.
Unruptured intracranial aneurysms - risk of rupture and risks of surgical intervention. International study of unruptured intracranial aneurysms investigators. N Engl J Med 1998;339:1725-1733.
9.
Wiebers DO, Whisnant JP, Huston J 3rd, et al: Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003;362:103-110.
10.
Chalouhi N, Ali MS, Jabbour PM, et al: Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab 2012;32:1659-1676.
11.
Chalouhi N, Ali MS, Starke RM, et al: Cigarette smoke and inflammation: role in cerebral aneurysm formation and rupture. Mediators Inflamm 2012;2012:271582.
12.
Ali MS, Starke RM, Jabbour PM, et al: TNF-α induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab 2013;33:1564-1573.
13.
Hasan DM, Mahaney KB, Brown RD Jr, et al: Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke 2011;42:3156-3162.
14.
Hasan DM, Chalouhi N, Jabbour P, et al: Evidence that acetylsalicylic acid attenuates inflammation in the walls of human cerebral aneurysms: preliminary results. J Am Heart Assoc 2013;2:e000019.
15.
Gross BA, Rosalind Lai PM, Frerichs KU, Du R: Aspirin and aneurysmal subarachnoid hemorrhage. World Neurosurg 2014;82:1127-1130.
16.
Hasan D, Chalouhi N, Jabbour P, et al: Early change in ferumoxytol-enhanced magnetic resonance imaging signal suggests unstable human cerebral aneurysm: a pilot study. Stroke 2012;43:3258-3265.
17.
Hasan D, Hashimoto T, Kung D, Macdonald RL, Winn HR, Heistad D: Upregulation of cyclooxygenase-2 (COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) in wall of ruptured human cerebral aneurysms: preliminary results. Stroke 2012;43:1964-1967.
18.
Hasan DM, Chalouhi N, Jabbour P, Magnotta VA, Kung DK, Young WL: Imaging aspirin effect on macrophages in the wall of human cerebral aneurysms using ferumoxytol-enhanced MRI: preliminary results. J Neuroradiol 2013;40:187-191.
19.
Chalouhi N, Jabbour P, Hasan D, Starke RM: Aspirin for prevention of subarachnoid hemorrhage: the stage is set for a randomized controlled trial. Neurosurgery 2014;74:E147-E148.
20.
Chalouhi N, Jabbour P, Starke RM, Hasan DM: Aspirin for prophylaxis against cerebral aneurysm rupture. World Neurosurg 2013;81:e2-e3.
21.
Starke RM, Chalouhi N, Ding D, et al: Vascular smooth muscle cells in cerebral aneurysm pathogenesis. Transl Stroke Res 2014;5:338-346.
22.
Weber C, Erl W, Pietsch A, Weber PC: Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995;91:1914-1917.
23.
Shackelford RE, Alford PB, Xue Y, Thai SF, Adams DO, Pizzo S: Aspirin inhibits tumor necrosis factoralpha gene expression in murine tissue macrophages. Mol Pharmacol 1997;52:421-429.
24.
Sánchez de Miguel L, de Frutos T, González-Fernández F, et al: Aspirin inhibits inducible nitric oxide synthase expression and tumour necrosis factor-alpha release by cultured smooth muscle cells. Eur J Clin Invest 1999;29:93-99.
25.
Hua Y, Xue J, Sun F, Zhu L, Xie M: Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology 2009;83:18-25.
26.
Chalouhi N, Points L, Pierce GL, Ballas Z, Jabbour P, Hasan D: Localized increase of chemokines in the lumen of human cerebral aneurysms. Stroke 2013;44:2594-2597.
27.
García-Rodríguez LA, Gaist D, Morton J, Cookson C, González-Pérez A: Antithrombotic drugs and risk of hemorrhagic stroke in the general population. Neurology 2013;81:566-574.
28.
van den Bergh WM; MASH Study Group, Algra A, Dorhout Mees SM, et al: Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH study. Stroke 2006;37:2326-2330.
29.
Chalouhi N, Jabbour P, Magnotta V, Hasan D: The emerging role of ferumoxytol-enhanced MRI in the management of cerebrovascular lesions. Molecules 2013;18:9670-9683.
30.
Hasan DM, Mahaney KB, Magnotta VA, et al: Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study. Arterioscler Thromb Vasc Biol 2012;32:1032-1038.
31.
Casado-Arroyo R, Sostres C, Lanas A: Optimizing the use of aspirin for cardiovascular prevention. Drugs 2013;73:803-814.
32.
Moncada S, Higgs EA, Vane JR: Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1977;1:18-20.
33.
Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G: Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 suppl):234S-264S.
34.
Ricciotti E, FitzGerald GA: Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011;31:986-1000.
35.
McAdam BF, Mardini IA, Habib A, et al: Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000;105:1473-1482.
36.
Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA: Prostanoids in health and disease. J Lipid Res 2009;50(suppl):S423-S428.
37.
Langenbach R, Loftin C, Lee C, Tiano H: Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem Pharmacol 1999;58:1237-1246.
38.
Morteau O, Morham SG, Sellon R, et al: Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 2000;105:469-478.
39.
Mulay SR, Gaikwad AB, Tikoo K: Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. Chem Biol Interact 2010;185:137-142.
40.
Lapponi MJ, Carestia A, Landoni VI, et al: Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 2013;345:430-437.
41.
Kaiser J: Will an aspirin a day keep cancer away? Science 2012;337:1471-1473.
42.
Berg M, Søreide K: Prevention: will an aspirin a day keep the colorectal cancer away? Nat Rev Clin Oncol 2011;8:130-131.
43.
Jacobs EJ: Will an aspirin a day help keep fatal cancer away? Lancet 2011;377:3-4.
44.
Garcia-Albeniz X, Chan AT: Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol 2011;25:461-472.
45.
Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
46.
Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
47.
Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-2581.
48.
Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT: Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995;15:1145-1151.
49.
Starke RM, Chalouhi N, Ali MS, et al: The role of oxidative stress in cerebral aneurysm formation and rupture. Curr Neurovasc Res 2013;10:247-255.
50.
Chimowitz MI, Lynn MJ, Derdeyn CP, et al: Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993-1003.
51.
Wong KS, Chen C, Fu J, et al: Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010;9:489-497.
52.
Grines CL, Bonow RO, Casey DE Jr, et al: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-818.
53.
Kikano GE, Brown MT: Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. Mayo Clin Proc 2007;82:583-593.
54.
Wang Y, Wang Y, Zhao X, Liu L, et al: Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11-19.
55.
Chimowitz MI, Lynn MJ, Howlett-Smith H, et al: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305-1316.
56.
Hankey GJ, Norman PE, Eikelboom JW: Medical treatment of peripheral arterial disease. JAMA 2006;295:547-553.
57.
Hiatt WR, Krantz MJ: The efficacy of aspirin in peripheral arterial disease: an unresolved question. J Mal Vasc 2007;32:71-72.
58.
Berger JS, Krantz MJ, Kittelson JM, Hiatt WR: Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009;301:1909-1919.
59.
Poredos P, Jezovnik MK: Is aspirin still the drug of choice for management of patients with peripheral arterial disease? Vasa 2013;42:88-95.
60.
Ait-Oufella H, Wang Y, Herbin O, et al: Natural regulatory T cells limit angiotensin II-induced aneurysm formation and rupture in mice. Arterioscler Thromb Vasc Biol 2013;33:2374-2379.
61.
Vorp DA, Lee PC, Wang DH, et al: Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening. J Vasc Surg 2001;34:291-299.
62.
Lindholt JS, Björck M, Michel JB: Anti-platelet treatment of middle-sized abdominal aortic aneurysms. Curr Vasc Pharmacol 2013;11:305-313.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.